DOLUTEGRAVIR efficacy in HIV infected patients

Dumitru, Irina Magdalena; Cernat, Roxana Carmen; Rugină, S.

doi:10.1515/arsm-2015-0019

Abstract

In the past years there have been numerous discoveries regarding treatment of patients with HIV. If at first the doctors watched as patients live longer, now we want these patients to live better with regimens potent, safe, individualized and without side effects. HAART has revolutionized “the world HIV” and caused a significant reduction in mortality, and morbidity associated with HIV-related opportunistic infections. However, side effects associated with HAART, metabolic toxicity (such as abnormal fat distribution, abnormal lipid and glucose metabolism, and bone loss) and the large number of pills led to decreased patient adherence.

References

1. Weller, I.V. & Williams, I.G. (2001). ABC of AIDS. Antiretroviral drugs. BMJ. 322(7299), 1410-1412
Search in Google Scholar
2. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Retrieved from http://aidsinfo.nih.gov/guidelines
Search in Google Scholar
3. Flexner, C. (1998). HIV protease inhibitors. N Engl J Med. 338, 1281-129310.1056/NEJM199804303381808
Search in Google Scholar
4. "U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay". From: Reuters. 12 August 2013.Retrieved 13 February 2013
Search in Google Scholar
5. EMA Tivicay information page. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002753/human_med_001720. jsp&mid=WC0b01ac058001d124
Search in Google Scholar
6. CSID: 25051637. (2014). Retrieved from http://www.chemspider.com/Chemical-Structure.25051637.html
Search in Google Scholar
7. Hare, S., Smith, S.J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S.H. & Cherepanov, P. (2011). Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 80(4), 565-57210.1124/mol.111.073189
Search in Google Scholar
8. Cottrell, M.L., Hadzic, T. & Kashuba, A.D. (2013). Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 52(11), 981-99410.1007/s40262-013-0093-2
Search in Google Scholar
9. FDA approves new drug to treat HIV infection. (2013). Retrieved from http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm364744.html
Search in Google Scholar
10. Min, S., Song, I. & Borland, J. et al. (2010). Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 54, 254-25810.1128/AAC.00842-09
Search in Google Scholar
11. Song, I., Borland, J. & Chen, S. et al. (2012). Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 56, 1627-162910.1128/AAC.05739-11
Search in Google Scholar
12. Letendre, S., Mills, A., Tashima, K., Thomas, D., Min, S., Chen, S., Song, I. & Piscitelli, S. (2013). Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results. CROI 2013. Poster 178LB
Search in Google Scholar
13. van Lunzen, J., Maggiolo, F., Arribas, J.R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J.K., Almond, S., Song, I., Brothers, C. & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis. 12(2), 111-11810.1016/S1473-3099(11)70290-0
Search in Google Scholar
14. Raffi, F., Rachlis, A., Stellbrink, H.J., Hardy, W.D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., Almond, S., Margolis, D., Brennan, C. & Min, S. (2013). SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviralnaive adults with HIV-1 infection: 48 week results from the randomized, double-blind, noninferiority SPRING-2 study. Lancet. 381(9868), 735-743
Search in Google Scholar
15. Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J.M., Baril, J.G., Domingo, P., Brennan, C., Almond, S. & Min, S. (2013). Extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, noninferiority trial. Lancet Infect Dis. 13(11), 927-935
Search in Google Scholar
16. Walmsley, S.L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., Pappa, K., Wynne, B., Min, S. & Nichols, G. (2013). SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 369(19), 1807-1818
Search in Google Scholar
17. Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., Harris, J., Brennan, C., Fujiwara, T. & Min, S. (2014). ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet. 383(9936), 2222-2231
Search in Google Scholar
18. Cahn, P., Pozniak, A.L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J.F., Richmond, G., Buendia, C.B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C.B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., Griffith, S. & Min, S. (2013). Extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomized, doubleblind, non-inferiority SAILING study. Lancet. 382(9893), 700-708
Search in Google Scholar
19. Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait- Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G. & Yeo, J.M. (2014). VIKING-3 Study Group. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 210(3), 354-362
Search in Google Scholar
20. Eron, J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C. & Yeo, J. for the VIKING Study Group (2013). Safety and efficacy of dolutegravir in treatmentexperienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 207(5), 740-74810.1093/infdis/jis750356330723225901
Search in Google Scholar
21. Cutillas, V., Mesplede, T., Anstett, K., Hassounah, S. & Wainberg, M.A. (2014). The addition of R262K to the H51Y mutation in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother. pii: AAC.04274-14. [Epub ahead of print]
Search in Google Scholar
22. Hardy, I., Brenner, B., Quashie, P., Thomas, R., Petropoulos, C., Huang, W., Moisi, D., Wainberg, M.A. & Roger, M. (2014). Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. pii: dku387. [Epub ahead of print]
Search in Google Scholar
23. Hightower, K.E., Wang, R., Deanda, F., Johns, B.A., Weaver, K., Shen, Y., Tomberlin, G.H., Carter, H.L. 3rd, Broderick, T., Sigethy, S., Seki, T., Kobayashi, M. & Underwood, M.R. (2011). Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 55(10), 4552-4559 10.1128/AAC.00157-11318700121807982
Search in Google Scholar
24. Underwood, M.R., Johns, B.A., Sato, A., Martin, J.N., Deeks, S.G. & Fujiwara, T. (2012). The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults. J Acquir Immune Defic Syndr. 61(3), 297-30110.1097/QAI.0b013e31826bfd02380431222878423
Search in Google Scholar
25. Johnson, M., Borland, J., Chen, S., Savina, P., Wynne, B. & Piscitelli, S. (2014). Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J ClinPharmacol. 78(5), 1043-104910.1111/bcp.12428424387824838177
Search in Google Scholar
26. Simeprevir (2013). FDA Antiviral Drugs Advisory Committee Meeting Briefing Document
Search in Google Scholar
27. Sofosbuvir for the Treatment of Chronic Hepatitis C Infection, Gilead Sciences (2013). Retrieved from http://www.gilead.com/news/press-releases/2013/12/us-food-and-drugadministration-approves-gileads-sovaldisofosbuvir-for-the-treatment-of-chronichepatitis-c
Search in Google Scholar
28. Dow, D.E. & Bartlett, J.A. (2014). Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infect Dis Ther. 3, 83-102 10.1007/s40121-014-0029-7426962625134686
Search in Google Scholar

DOLUTEGRAVIR efficacy in HIV infected patients

Abstract

Paradigm

My account